Use of Dawnzera (donidalorsen) — approved in the U.S. as a preventive treatment for hereditary angioedema (HAE) in patients ages 12 and older — led to sustained reductions in the rate of swelling attacks, accompanied by quality of life improvements, for as long as nearly four years among…